Continuous Wireless Ultrasound to Monitor Fetal Health

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorBoston Children's Hospital

About this trial

This study is a single-center, prospective, and non-randomized feasibility study designed to evaluate the practicality, tolerability, and data quality of short-duration continuous fetal monitoring using a wireless bioadhesive ultrasound device. The study involves a single visit per participant and does not include any therapeutic intervention.

Eligible participants will undergo placement of a wireless bioadhesive ultrasound (ABAUS) device on the maternal abdomen for a short-duration monitoring session. The device will acquire continuous or semi-continuous ultrasound data for a total of 10-30 minutes per participant, without altering standard clinical care. The study is observational and is intended to assess the technical feasibility of device placement, the stability of the coupling during routine maternal movement, image quality over time, and the ability to monitor fetal motion, heart rate, and uterine activity using the investigational device under controlled yet realistic clinical conditions.

The study is non-interventional. No diagnostic or therapeutic decisions will be made based on the ultrasound data collected as part of this research protocol, and all standard prenatal care will proceed independently of participation in this study.

Eligibility criteria

Qualifiers

Pregnant individual 18 years or older

Singleton uterine pregnancy

Gestational age 20 to 39 gestational weeks

Able to provide written informed consent

Disqualifiers

Multiple gestation

Maternal abdominal skin condition at the potential site of attachment, such as rash, open wound, etc., preventing placement

Known allergy or hypersensitivity to adhesive material or hydrogel products

Need for urgent clinical management/triage

Trial design

Treatments tested in this trial

  • Wireless Ultrasound Device

Treatment groups

50 Participants
are divided into 1 treatment group

Sponsors and collaborators

Boston Children's Hospital

Lead sponsor

Massachusetts Institute of Technology

Collaborator